C4 Therapeutics (NASDAQ: CCCC) director receives 62,000 stock options at $4.25

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

C4 Therapeutics, Inc. director Owen Hughes received a grant of stock options covering 62,000 shares of common stock. The options have an exercise price of $4.2500 per share and expire on June 23, 2036. Following this grant, Hughes holds options on 62,000 shares directly.

According to the vesting terms, the option becomes fully exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, provided Hughes continues serving on the Board through that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hughes Owen

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	62,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 62,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 62,000 options Exercise price: $4.2500 per share Expiration date: June 23, 2036 +3 more

6 metrics

Option grant size 62,000 options Stock Option (Right to Buy) awarded to director Owen Hughes

Exercise price $4.2500 per share Exercise price for options on C4 Therapeutics common stock

Expiration date June 23, 2036 Option expiration for the 62,000-share grant

Underlying shares 62,000 shares Common stock underlying the granted options

Post-grant derivative holdings 62,000 options Total options held directly after this transaction

Vesting latest date June 24, 2027 Latest possible full vesting date, subject to continued Board service

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, vest and become exercisable, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "4.2500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"This option shall vest and become exercisable in full upon the earlier"

annual meeting of the Issuer's stockholders financial

"the next annual meeting of the Issuer's stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 08:33 PM Accepted by SEC EDGAR 06/26/2026 - 08:33 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hughes Owen

(Last)

(First)

(Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$4.25	06/24/2026		A		62,000		⁽¹⁾	06/23/2036	Common Stock	62,000	$0	62,000	D

Explanation of Responses:

1. This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Owen Hughes report in the latest CCCC Form 4 filing?

Owen Hughes reported receiving stock options for 62,000 C4 Therapeutics shares. These options were granted at an exercise price of $4.25 per share and represent compensation for his service as a director, increasing his derivative holdings to 62,000 options.

What are the key terms of Owen Hughes’ 62,000 C4 Therapeutics options?

The options cover 62,000 C4 Therapeutics common shares at a $4.25 exercise price. They expire on June 23, 2036, and will vest in full if Hughes remains on the Board until June 24, 2027 or the next annual stockholder meeting, whichever occurs first.

When do Owen Hughes’ new CCCC stock options vest and become exercisable?

The options vest and become fully exercisable on the earlier of June 24, 2027 or the next C4 Therapeutics annual stockholder meeting. Vesting is conditioned on Hughes’ continued service as a Board member through that date, as described in the filing footnote.

How many C4 Therapeutics shares can be purchased under Owen Hughes’ new options?

The grant allows purchase of 62,000 C4 Therapeutics common shares upon exercise. Each option share is exercisable at $4.25, once vesting conditions are met and before the June 23, 2036 expiration date, giving Hughes a potential future equity stake via this award.

Is Owen Hughes’ Form 4 transaction a market purchase or sale of CCCC stock?

The Form 4 shows a grant of stock options, not a market trade in C4 Therapeutics shares. The transaction is coded as an award (Code A), indicating compensation-related acquisition of derivative securities rather than an open-market buy or sell of common stock.

What is Owen Hughes’ reported C4 Therapeutics option position after this grant?

After the award, Hughes is reported as directly holding options on 62,000 C4 Therapeutics shares. The filing lists this as the total derivative position following the transaction, with no additional remaining derivative holdings shown in the derivative summary section.